Novel therapies for Duchenne muscular dystrophy.
The development of therapeutic strategies that overcome the unique problems posed by Duchenne muscular dystrophy (DMD) has lead to the development of many contemporary approaches to human disease in general. Various treatment approaches have been explored--such as pharmacological therapies and cell-based, cytokine, and genetic therapies--that are all targeted to specific features of dystrophic DMD muscle pathology. In genetic therapies, the large size of the dystrophin gene has necessitated the development and use of novel functional minidystrophin and microdystrophin genes, muscle-specific promoter systems, and gutted adenoviral systems. In addition to these well defined viral strategies, plasmid vectors and the upregulation of utrophin (a dystrophin homologue) have potential. Various novel genetic approaches--such as antisense-mediated exon skipping, gene correction, and new cytokine approaches--are also being developed. Together these exciting developments bring an effective treatment for DMD closer than ever before.
Kapsa
Robert
R
Melbourne Neuromuscular Research Institute, Fitzroy, the Howard Florey Institute, Parkville, Australia. rkapsa@iinet.net.au <rkapsa@iinet.net.au>
Kornberg
Andrew J
AJ
Byrne
Edward
E
D064987:Cell- and Tissue-Based Therapy; D016189:Dystrophin / Q000235:genetics; D005785:Gene Conversion; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000473:pathology / Q000628:therapy*
D016189:Dystrophin